Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.52 |
| ▸ | ABAT | P80404 | 1/20 | 0.52 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL910063 | 0.84 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1TSHRNFKB1 | |
| SCHEMBL56335 | 0.81 | CA2 (0.48) | ALDH1A1TDP1HPGDTSHRGAA | |
| SCHEMBL459931 | 0.80 | MAOB (0.55) | MAOBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL15012969 | 0.80 | MAOB (0.55) | MAOBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL29084199 | 0.80 | MAOB (0.55) | MAOBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL5974207 | 0.80 | MAOB (0.55) | MAOBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL29804271 | 0.80 | MAOB (0.55) | MAOBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL6899032 | 0.79 | ALDH1A1 (0.56) | MEN1RAB9AKMT2AALDH1A1HPGD | |
| SCHEMBL18130098 | 0.78 | MAOB (0.64) | MAOBSLC22A6SLC22A8MEN1RAB9A | |
| SCHEMBL6302783 | 0.78 | PTGS2 (0.50) | MEN1KMT2AALDH1A1TDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784991-A | N- (benzenesulfonyl) amide derivative and preparation method and application thereof | 合肥医工医药股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20090324750-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| EP-1904054-A4 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY | KOREA RES INST OF BIOSCIENCE (KR) | 2008-12-31 | — | — | EP | claimed |
| JP-2008542363-A | — | — | 2008-11-27 | — | — | JP | claimed |
| EP-1904054-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY | Korea Research Institute of Bioscience and Biotechnology (KR) | 2008-04-02 | — | — | EP | claimed |
| WO-2006129964-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-12-07 | — | — | WO | claimed |
| US-20050101541-A1 | Lignan derivatives | HORMOS MEDICAL CORPORATION (FI) | 2005-05-12 | — | — | US | claimed |
| EP-1472206-A1 | LIGNAN DERIVATIVES | Hormos Medical Corporation (FI) | 2004-11-03 | — | — | EP | claimed |
| EP-1171130-A4 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME | GUILFORD PHARM INC (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2003066556-A1 | LIGNAN DERIVATIVES | HORMOS MEDICAL CORPORATION (FI) | 2003-08-14 | — | — | WO | claimed |
| US-20030078212-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME | GUILFORD PHARMACEUTICALS INC. | 2003-04-24 | — | — | US | claimed |
| JP-2002540060-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1171130-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME | GUILFORD PHARMACEUTICALS INC. (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000025787-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME | GUILFORD PHARMACEUTICALS INC. (US) | 2000-05-11 | — | — | WO | claimed |
| JP-2180846-A | — | — | None | — | — | JP | disclosed |
| JP-4275296-A | — | — | None | — | — | JP | disclosed |
| CN-115784991-A | N- (benzenesulfonyl) amide derivative and preparation method and application thereof | 合肥医工医药股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-4785010-A | AGING RESISTANCE OF HUMANS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0124067-B1 | 2-(AMINOALKYL)-PYRROLE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | CASSELLA Aktiengesellschaft (DE) | 1986-12-17 | — | — | EP | disclosed |
| EP-0124067-A1 | 2-(Aminoalkyl)-pyrrole derivatives, process for their manufacture and their use | CASSELLA Aktiengesellschaft (DE) | 1984-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324750-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF PSEUDOLYSIMACHION LONGIFOLIUM AND THE CATALPOL DERIVATIVES ISOLATED THEREFROM HAVING ANTIINFLAMMATORY, ANTIALLERGIC AND ANTIASTHMATIC ACTIVITY | IL4, IL5, MMP13 | MAOB 3325/4885SLC22A6 2474/4885SLC22A8 4018/4885 |
| US-20050101541-A1 | Lignan derivatives | EBP, ELOVL3, LCT | MAOB 2671/4885SLC22A6 880/4885SLC22A8 684/4885 |
| US-20030078212-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLY(ADP-RIBOSE) GLYCOHYDROLASE INHIBITORS AND METHODS OF USING THE SAME | PARP10, PARG, DERA | MAOB 2436/4885SLC22A6 1309/4885SLC22A8 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.